IP Library Granted Patent US 8,163,879
Granted Patent B2
US 8,163,879 · App. 12/700,949 · Granted Apr 24, 2012

Fusion molecules and IL-15 variants

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,163,879
App. No.
12/700,949
Granted
Apr 24, 2012
Kind
B2
Abstract

The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the such proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.

Claims (9)

1. An isolated human interleukin 15 (hIL-15) variant comprising an amino acid substitution at position 61, 72, 92, or 111 of a mature human IL-15 sequence of SEQ ID NO:1, wherein the hIL-15 variant has increased or decreased binding activity for the interleukin 15 receptor beta/gamma chain (IL-15RβγC) receptors compared to native hIL-15 polypeptide.

2. The isolated hIL-15 variant of claim 1 , wherein the hIL-15 variant functions as an IL-15 agonist or antagonist.

3. The isolated hIL-15 variant of claim 1 , where the amino acid substitution is in the domain of IL-15 that interacts with IL-15RβγC, or both IL-15Rβ and γC.

4. The isolated hIL-15 variant of claim 1 , wherein the amino acid substitution is of D to A at position 61 or N to R at position 72 of the mature human IL-15 sequence.

5. The isolated hIL-15 variant of claim 4 , wherein the amino acid substitution results in an hIL-15 variant that has IL-15 antagonist activity or decreased binding activity for the IL-15RβγC receptors compared to the native hIL-15 polypeptide.

6. The isolated hIL-15 variant of claim 1 , wherein the amino acid substitution is of N to D at position 72 of the mature human IL-15 sequence.

7. The isolated hIL-15 variant of claim 6 , wherein the amino acid substitution results in an IL-15 variant that has IL-15 agonist activity or increased binding activity for the IL-15RβγC receptors compared to the native hIL-15 polypeptide.

8. An isolated human interleukin 15 (hIL-15) variant, comprising an amino acid substitution at position 72 of a mature human IL-15 sequence.

9. The isolated hIL-15 variant of claim 8 , wherein the amino acid substitution is selected from the group consisting of alanine, aspartic acid, and arginine.

Assignments (3)
SECURITY INTEREST Recorded Jan 2, 2024
From: IMMUNITYBIO, INC.; NANTCELL, INC.; RECEPTOME, INC.; VBC HOLDINGS LLC; ALTOR BIOSCIENCE, LLC; ETUBICS CORPORATION; IGDRASOL, INC.
To: INFINITY SA LLC, AS PURCHASER AGENT
Reel/Frame 066179/0074 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2022
From: WONG, HING C.; RHODE, PETER; ZHU, XIAOYUN; HAN, KAI-PING
To: ALTOR BIOSCIENCE CORPORATION
Reel/Frame 061198/0903 →
MERGER AND CHANGE OF NAME Recorded Sep 4, 2019
From: ALTOR BIOSCIENCE CORPORATION; ALTOR BIOSCIENCE LLC
To: ALTOR BIOSCIENCE LLC
Reel/Frame 050260/0522 →